Sequenom's Q2 Revenues Rise 17 Percent as It Names T21 Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its second-quarter revenues jumped 17 percent as sales rose for its genetic analysis products and diagnostic services.

The San Diego-based molecular diagnostics developer brought in total revenues of $13.3 million for the three months ended June 30, compared to revenues of $11.4 million for the second quarter of 2010. It missed Wall Street's estimate of $13.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.